Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Patient Assistance Program Will Cover Newly Approved Tykerb

This article was originally published in The Pink Sheet Daily

Executive Summary

Tyrosine kinase inhibitor clears FDA March 13 for use in combination with Roche’s Xeloda for second-line treatment of advanced or metastatic HER2 positive breast cancer.

You may also be interested in...



GSK Study Shows Tykerb/Herceptin Combo Increases Progression-Free Survival In Breast Cancer

Firm unveils positive Phase III data in women with HER-2 positive metastatic breast cancer weeks ahead of ASCO annual meeting.

GSK Study Shows Tykerb/Herceptin Combo Increases Progression-Free Survival In Breast Cancer

Firm unveils positive Phase III data in women with HER-2 positive metastatic breast cancer weeks ahead of ASCO annual meeting.

National Cancer Institute Kicks Off Head-To-Head Tykerb vs. Herceptin Study

Enrollment could exceed global targets, principal investigator tells “The Pink Sheet” Daily.

Related Content

Topics

UsernamePublicRestriction

Register

PS065748

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel